Free tool
Drug Trial Radar: Rare and genetic disease
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
16
Recruiting, industry sponsors, Rare and genetic disease, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed111
16 trials
Showing 1 to 16, recently updated first.
JCR Pharmaceuticals Co., Ltd.Industry
NCT07640984 · 12 participants (planned) · Start Sep 9, 2026 · Primary completion Jun 30, 2028
Drug: JR-446 · For: Mucopolysaccharidosis IIIB
Sites: Oakland, California; Pittsburgh, Pennsylvania; Fairfax, Virginia · 5 sites in all
Denali Therapeutics Inc.Industry
NCT07354724 · 32 participants (planned) · Start May 12, 2026 · Primary completion Aug 2028
Drug: DNL952 · For: Late-onset Pompe Disease
Sites: Irvine, California; St Louis, Missouri; Durham, North Carolina · 8 sites in all
Kyowa Kirin Co., Ltd.Industry
NCT06525636 · 39 participants (planned) · Start Oct 9, 2024 · Primary completion Jun 14, 2030
Drug: KK8123 · For: X-linked Hypophosphatemia
Sites: San Francisco, California; New Haven, Connecticut; Indianapolis, Indiana · 10 sites in all
Denali Therapeutics Inc.Industry
NCT06181136 · 30 participants (planned) · Start Dec 7, 2023 · Primary completion Jul 2032
Drug: DNL126; Prophylactic immunomodulatory therapy · For: Mucopolysaccharidosis Type IIIA
Sites: Oakland, California; Iowa City, Iowa; Chapel Hill, North Carolina · 4 sites in all
- A Study of MZE782 in Adults With PKURecruiting
Maze TherapeuticsIndustry
NCT07694440 · 38 participants (planned) · Start Jun 23, 2026 · Primary completion Dec 2027
Drug: MZE782; MZE782 · For: Phenylketonuria (PKU)
Sites: Oakland, California; Palo Alto, California; Chicago, Illinois · 9 sites in all
- RAPA-501 Therapy for ALSPivotal-lookingRecruiting
Rapa Therapeutics LLCIndustry
NCT04220190 · 41 participants (planned) · Start Jan 2, 2025 · Primary completion Jul 1, 2027
Drug: RAPA-501 Autologous T stem cells · For: Amyotrophic Lateral Sclerosis
Sites: Boston, Massachusetts
UniQure Biopharma B.V.Industry
NCT06270316 · 20 participants (planned) · Start Jun 5, 2024 · Primary completion Dec 1, 2027
Drug: AMT-191 · For: Fabry Disease
Sites: Birmingham, Alabama; Los Angeles, California; Atlanta, Georgia · 10 sites in all
- Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSHPivotal-lookingRecruiting
Ultragenyx Pharmaceutical IncIndustry
NCT02716246 · 36 participants (planned) · Start Apr 25, 2016 · Primary completion Mar 2029
Drug: UX111; Prophylactic Immunomodulatory (IM) Therapy and 2 more · For: MPS IIIA; Sanfilippo Syndrome; Sanfilippo A and 1 more
Sites: Columbus, Ohio; Pittsburgh, Pennsylvania; North Adelaide, Australia · 5 sites in all
- A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry DiseasePivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT06328608 · 22 participants (planned) · Start Jul 29, 2025 · Primary completion Oct 2028
Drug: PRX-102 1 mg/kg every two weeks · For: Fabry Disease
Sites: Phoenix, Arizona; Atlanta, Georgia; Iowa City, Iowa · 12 sites in all
Connecta Therapeutics, S.L.Industry
NCT07654114 · 30 participants (planned) · Start May 21, 2026 · Primary completion May 2027
Drug: CTH120 · For: Fragile X Syndrome (FXS); Fragile X Syndrome
Sites: Barcelona, Spain; Sabadell, Spain
QED Therapeutics, a BridgeBio companyIndustry
NCT07169279 · 77 participants (planned) · Start Nov 19, 2025 · Primary completion Mar 2030
Drug: Infigratinib is provided as a single dose of minitablets for oral administration; Infigratinib is provided as sprinkle capsules for daily oral administration and 2 more · For: Achondroplasia
Sites: Oakland, California; Baltimore, Maryland; Madison, Wisconsin · 12 sites in all
ShionogiIndustry
NCT07123155 · 45 participants (planned) · Start Oct 30, 2025 · Primary completion Aug 8, 2027
Drug: S-606001; Placebo · For: Pompe Disease
Sites: Irvine, California; Gainesville, Florida; Atlanta, Georgia · 28 sites in all
- A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)Recruiting
Aspa TherapeuticsIndustry
NCT04998396 · 26 participants (planned) · Start Sep 8, 2021 · Primary completion Oct 13, 2026
Drug: AAV9 BBP-812 · For: Canavan Disease
Sites: Oakland, California; Chicago, Illinois; Boston, Massachusetts · 4 sites in all
- Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry DiseasePivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT05710692 · 16 participants (planned) · Start Aug 1, 2023 · Primary completion Oct 2027
Drug: PRX-102 1 mg/kg every 2 weeks; PRX-102 2 mg/kg every 4 weeks · For: Fabry Disease
Sites: Chikushino-shi, Japan; Sendai, Japan; Nishihara, Japan · 10 sites in all
GC Biopharma CorpIndustry
NCT06858397 · 18 participants (planned) · Start May 14, 2025 · Primary completion Aug 30, 2028
Drug: HM15421/GC1134A · For: Fabry Disesase
Sites: Los Angeles, California; Kansas City, Kansas; Minneapolis, Minnesota · 10 sites in all
4D Molecular TherapeuticsIndustry
NCT05629559 · 18 participants (planned) · Start Oct 16, 2022 · Primary completion Jun 2026
Drug: 4D-310 · For: Fabry Disease
Sites: Melbourne, Australia; Perth, Australia; Westmead, Australia · 4 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.